Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06217796 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy of Fixed Combination Phenylephrine-Tropicamide for Pupil Dilation
A Phase 4 study, sponsored by Eyenovia.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT06217796: Completed Phase 4 study, sponsored by Eyenovia.
NCT06217796 is a Phase 4 study that has completed, run by Eyenovia. The registered enrollment target is 30 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06217796, a Phase 4 study, has completed, sponsored by Eyenovia.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
Subjects will receive ½ of the approved dose of MydCombi to determine the dilation curve with the reduced dose.
Primary Outcome
Mean change in pupil diameter at 30 minutes from the time of drug dose versus baseline, as measured by digital pupillometry in highly photopic conditions
Interventions
- COMBINATION_PRODUCT MydCombi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-11-28 |
| Est. Completion | 2024-01-09 |
| Phase | Phase 4 |
What the finished NCT06217796 record still lists
NCT06217796 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which MydCombi is the first listed.
NCT06217796 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06217796 about?
NCT06217796 is a clinical study titled "Safety and Efficacy of Fixed Combination Phenylephrine-Tropicamide for Pupil Dilation". Subjects will receive ½ of the approved dose of MydCombi to determine the dilation curve with the reduced dose.
What is the current status of trial NCT06217796?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2023-11-28. Estimated completion is 2024-01-09.
What interventions are being tested in trial NCT06217796?
The interventions under investigation include: MydCombi (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06217796?
This trial is sponsored by Eyenovia, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06217796's enrollment target sits among peer trials
30 1552nd of 2000 higher than 367 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI